ORGO earnings call for the period ending September 30, 2024. Organogenesis ( ORGO -1.43%) Q3 2024 Earnings Call Nov 12, 2024, ...

Organogenesis (ORGO) announced the favorable outcome of the interim analysis of its second Phase 3 randomized control trial of ReNu, a ...

Organogenesis is the process by which the internal organs and specific structures such as the limb are formed during development of an organism. Organogenesis involves the coordination of multiple ...

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and ...

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of ...

As the U.S. stock market navigates the uncertainty surrounding the presidential election and upcoming Federal Reserve interest rate decisions, investors are keeping a close eye on various sectors for ...

Organogenesis Holding (ORGO) reported Q4 EPS of $0.06, in-line with the analyst estimate of $0.06. Revenue for the quarter came in at $115.5 million versus the consensus estimate ...

Robust 218-patient RCT demonstrates statistically superior frequency of wound closure at 12 weeks compared to standard of care (p=.04) Organogenesis believes published study ...

But really bad investments should be rare. So take a moment to sympathize with the long term shareholders of Organogenesis Holdings Inc. (NASDAQ:ORGO), who have seen the share price tank a massive ...

Organogenesis is a regenerative medicine company with an advanced wound care niche, and it's looking to take over a manufacturing site in Rhode Island. A Boston-based biotechnology firm could be ...

ReNu Energy Limited (AU:RNE) has released an update. ReNu Energy Limited has issued 838,750,000 ordinary shares and several unlisted options as part of a recent capital raise, approved in a ...